Gentle Monster Plots 60+ Global Stores as K-Eyewear Goes Upscale in Paris, Milan, and New York

The Quick Take

• Gentle Monster, operated by I.I.Combined, runs 86 stores worldwide with about 50 overseas, and international markets already generate roughly 40% of total revenue.
• The company plans to expand to 60 overseas stores in 2026, then grow further across the US, Canada, Europe, and major Asian markets over a 3-5 year horizon.
• Flagships in Paris Marais and Milan (via 10 Corso Como) mark completion of Gentle Monster's presence in all four global fashion capitals — building on New York and London.
• South Korea's K-bio sector is navigating an investor-trust deficit after the "Samchundang Shock," with companies restricting media access in ways that risk compounding credibility concerns.

Gentle Monster, the Seoul-headquartered luxury eyewear brand operated by I.I.Combined, is accelerating an aggressive global offline expansion that now spans 86 stores worldwide, with approximately 50 of those located internationally and contributing around 40% of total group revenue. The brand's 2026 target — lifting overseas stores from roughly 50 to 60 — is the foundation of a broader 3-5 year push into the US, Canada, Europe, and principal Asian markets, with smart-glasses and next-generation eyewear as an additional product growth driver. Crucially, the Paris Marais flagship drew around 1,000 visitors per day at opening, while the Milan entry via 10 Corso Como provides high-visibility positioning within the luxury retail ecosystem.

The retail economics of this expansion carry visible risk alongside the growth narrative: the "aggressive investment" phase has created margin pressure, and the company must now demonstrate profitability and sustainability alongside revenue expansion. In the luxury sector, offline flagship density is both a brand-equity signal and a fixed-cost commitment — markets like New York and Milan carry some of the highest retail real-estate costs globally. If foot traffic and conversion rates at the new European flagships match the Paris experience, the model is viable; if they fall short, the cost structure could strain operating leverage. K-bio's parallel investor-trust crisis post-Samchundang Shock is a reminder that Korean companies targeting global credibility must prioritise transparent stakeholder communication as a capital markets imperative.

Watch I.I.Combined's next earnings disclosure for operating margin trends on the international segment — the key signal that global store economics are reaching self-sustaining profitability rather than relying on Korea-side cross-subsidy. Smart-glasses partnerships or licensing deals with major tech or telecom players would be a material catalyst if announced in the 3-5 year window. For the K-bio sector, regulatory clarity on clinical trial disclosure standards is the event that would most directly resolve the post-Samchundang trust deficit and restore institutional investor confidence in Korean biotech listings.

Synthesized from 2 sources.